Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update
Rhea-AI Summary
Onconetix (Nasdaq: ONCO) disclosed that Realbotix expects to deliver 19 previously ordered humanoid robots and related AI implementations across March, April, and May 2026 as it scales production capacity. Onconetix previously entered a definitive all-stock share exchange to acquire Realbotix LLC, with closing anticipated in 2H 2026, subject to shareholder and regulatory approvals. This update is provided for informational purposes and includes forward-looking statements; investors are cautioned against undue reliance.
AI-generated analysis. Not financial advice.
Positive
- 19 robots scheduled for delivery in March–May 2026
- Definitive all-stock agreement to acquire Realbotix LLC
- Combined company expected to trade on Nasdaq after closing in 2H 2026
Negative
- Closing conditional on shareholder approval and regulatory clearances
- Timing risk—close anticipated in 2H 2026 but not guaranteed
- Forward-looking information may not materialize as planned
News Market Reaction – ONCO
On the day this news was published, ONCO declined 18.94%, reflecting a significant negative market reaction. Argus tracked a trough of -24.4% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $314K from the company's valuation, bringing the market cap to $1.34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ONCO gained 25.85% while close biotech peers were mixed: APVO -1.99%, OGEN -3.58%, QNRX -8.18%, XBIO +1.08%, SXTP +6.86%. This points to company-specific reaction to the Realbotix update rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 31 | Leadership changes | Positive | -5.1% | New CEO and director appointments tied to advancing Realbotix acquisition. |
| Mar 25 | AI/6G collaboration | Positive | +5.7% | Realbotix humanoid featured in Ericsson pre-standard 6G trial demo. |
| Mar 23 | Reverse stock split | Negative | -3.0% | 1-for-5 reverse split to support Nasdaq minimum bid compliance. |
| Feb 12 | Realbotix acquisition | Positive | -42.7% | All-stock deal to acquire 100% of Realbotix LLC and remain on Nasdaq. |
| Feb 12 | Seller deal announcement | Positive | -42.7% | Realbotix parent announces sale of subsidiary to Nasdaq-listed Onconetix. |
News tied to the Realbotix acquisition has often seen sharp, sometimes negative, price reactions, while operational AI/robotics highlights and reverse split actions produced smaller, directionally intuitive moves.
Over the last few months, Onconetix has pivoted around the planned acquisition of AI humanoid robotics company Realbotix. The initial deal announcement on Feb 12, 2026 and related seller communication coincided with steep -42.7% moves, suggesting shareholder concern over dilution and control. Subsequent corporate actions included a 1‑for‑5 reverse split on Mar 23, 2026 and leadership changes on Mar 31, 2026 to support the strategy. A Mar 25, 2026 highlight of Realbotix’s role in Ericsson’s 6G trial saw a modest positive reaction, similar in theme to today’s update on robot deliveries and scaling production.
Market Pulse Summary
The stock dropped -18.9% in the session following this news. A negative reaction despite operational progress on Realbotix robot deliveries would fit a pattern where the market has sometimes discounted this transaction. The initial all-stock acquisition announcement saw a steep -42.7% move, and the 1‑for‑5 reverse split also coincided with weakness. In such a scenario, concerns around dilution, control shifts, and prior going-concern language in filings could weigh more heavily than the incremental AI/robotics update, reinforcing the stock’s history of sharp deal-related swings.
Key Terms
definitive agreement financial
all-stock transaction financial
regulatory approvals regulatory
AI-generated analysis. Not financial advice.
Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp.
CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix’s previously announced pending acquisition.
On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and May of 2026. The company continues to develop its pipeline as it moves to scale its production capacity and increase demand for its humanoids and AI. Onconetix is sharing this development with its shareholders as it relates to Realbotix, the target of the pending acquisition.
As previously announced on February 12, 2026, Onconetix entered into a definitive share exchange agreement to acquire
This communication includes information regarding Realbotix, a company that Onconetix has agreed to acquire, and is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.
Additional Information and Where to Find It
In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.
A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com
